Skye launched its Phase 2 trial of nimacimab in obesity in August 2024. This trial, which is the first to also assess a GLP-1/CB1 inhibitor combination, is expected to report interim weight loss data ...

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

A gradual descent seems the most likely scenario.To be sure, the stock market is still digesting what the Fed has done.

The House and Senate are racing to complete the government funding process with the Sept. 30 shutdown deadline looming and lawmakers eager to head back to their districts to campaign ahead of the ...

Sen. Mike Braun has a unique opportunity to hold Novo Nordisk accountable for discontinuing insulin drug Levemir.

A Senate hearing Tuesday will look at why the list prices of Ozempic and Wegovy are much higher in the U.S. than in ...

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of ...

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. Read the ...

Ozempic is a popular diabetes drug that is also used for weight loss by suppressing appetite. Sanders expressed confidence ...

Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...

Danish Prime Minister Mette Frederiksen said she’s “extremely proud” of the country’s corporate champions, and rejected ...